You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 基石藥業-B(2616.HK)大漲逾9% 抑制劑普吉華擴展適應症申請獲受理
格隆匯 04-27 11:45
格隆匯4月27日丨基石藥業-B(2616.HK)大幅拉昇漲9.35%,報10.58港元創2個月新高價,總市值124億港元。基石藥業-B26日公佈,選擇性RET抑制劑普吉華(普拉替尼膠囊)擴展適應症申請已獲中國國家藥品監督管理局受理並被納入優先審評。普吉華是中國首個獲批的選擇性RET抑制劑,由基石藥業合作伙伴Blueprint Medicines公司(NASDAQ:BPMC)開發。公司的普吉華針對甲狀腺癌的適應症獲得NMPA受理,這比原計劃提前了6個月。研究資料顯示在RET突變的甲狀腺髓樣癌和RET融合陽性的甲狀腺癌患者中,普吉華表現出優異且持久的療效以及良好的耐受性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account